Patents by Inventor Robert B. Stein

Robert B. Stein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
    Patent number: 6096787
    Abstract: In accordance with the present invention, there is provided a method for the treatment of subjects afflicted with steroid or steroid-like hormone-responsive disease states. The invention method comprises administering to the subject an effective amount of a ligand which selectively interacts with the receptor subtype associated with the steroid or steroid-like hormone-responsive disease state, wherein said ligand interacts with said receptor subtype to a significantly greater extent than with other subtypes of the same receptor class.
    Type: Grant
    Filed: September 16, 1997
    Date of Patent: August 1, 2000
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Richard A. Heyman, Christina S. Berger, Robert B. Stein
  • Non-steroid progesterone receptor agonist and antagonist and compounds and methods
    Patent number: 5808139
    Abstract: Non-steroidal compounds which are high affinity, high specificity ligands for progesterone receptors are disclosed. The compounds include synthetic derivatives of cyclocymopol and its diastereomers, spectroscopically and chromatographically pure (3R)-cyclocymopol monomethyl ether, which functions as a progesterone receptor antagonist, and spectroscopically and chromatographically pure (3S)-cyclocymopol monomethyl ether, which functions as a progesterone receptor agonist. Also disclosed are methods for employing the disclosed compounds for modulating processes mediated by progesterone receptors and for treating patients requiring progesterone receptor agonist or antagonist therapy.
    Type: Grant
    Filed: September 8, 1994
    Date of Patent: September 15, 1998
    Assignees: Ligand Pharmaceuticals Incorporated, The Regents of the University of California
    Inventors: I. Charles Pathirana, Christina S. Berger, Robert B. Stein, William Fenical, Todd K. Jones, Lawrence G. Hamann, Michael G. Johnson, Luc Farmer
  • Use of selective ligands for treatment of disease states responsive to steroid or steroid-like retinoids
    Patent number: 5668175
    Abstract: In accordance with the present invention, there is provided a method for the treatment of subjects afflicted with steroid or steroid-like hormone-responsive disease states. The invention method comprises administering to the subject an effective amount of a ligand which selectively interacts with the receptor subtype associated with the steroid or steroid-like hormone-responsive disease state, wherein said ligand interacts with said receptor subtype to a significantly greater extent than with other subtypes of the same receptor class.
    Type: Grant
    Filed: August 12, 1996
    Date of Patent: September 16, 1997
    Assignee: The Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Richard A. Heyman, Christina S. Berger, Robert B. Stein
  • Inhibitor of ribonucleotide reductase
    Patent number: 4845195
    Abstract: The pentapeptide Val Val Asn Asp Leu has been found to be the shortest peptide sequence that inhibits the activity of the ribonucleotide reductase enzyme of herpes simplex virus in vitro thereby inhibiting viral replication. Longer peptides containing the foregoing pentapeptide sequence are more potent inhibitors.
    Type: Grant
    Filed: May 22, 1987
    Date of Patent: July 4, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Richard Colonno, Victor M. Garsky, John Hannah, Robert B. Stein, Richard L. Tolman
  • Inhibitor of ribonucleotide reductase
    Patent number: 4814432
    Abstract: A series of peptides has been found to inhibit the activity of the ribonucleotide reductase enzyme of herpes simplex virus in vitro thereby inhibiting viral replication.
    Type: Grant
    Filed: May 22, 1987
    Date of Patent: March 21, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Roger Freidinger, John Hannah, Victor M. Garsky, Robert B. Stein, Richard L. Tolman